J&J’s Prostate Cancer Combo Shows Promise, As Phase III Proceeds
J&J wants to maintain a leading position in prostate cancer with pasritamig and other agents, with first results from its combination with JNJ-9401.
Scrip - November 9, 2026

Scrip’s Five Must-Know Things: Madrigal’s MASH Whistleblower, Lilly, Sanofi Hunt Deals
In this week's episode: Madrigal’s MASH whistleblower; Lilly’s dealmaking to continue; Sanofi hunting late-stage assets; Pfizer raises guidance; and LIB’s PCSK9 pricing.
Scrip - November 9, 2026

Global Medtech Guidance Tracker: October 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. More than 40 documents have been posted on the tracker since its last update.
Medtech Insight - November 6, 2026

BD Growth Platforms Lead Fourth Quarter As Alaris Comparison Weighs On Fiscal 2027
BD’s fiscal fourth-quarter revenue rose 5.6% on a currency-neutral basis to $5.27bn, and adjusted EPS climbed 27.3% to $4.15. The CEO said growth platforms led the quarter and that mid-single-digit revenue growth should return as the Alaris comparison eases.
Medtech Insight - November 6, 2026

Device Makers Should Start Preparing For FDA GenAI Oversight Now, MethodSense CEO Says
MethodSense CEO Rita King says device makers need not wait for FDA guidance on generative AI to prepare. She expects a focus on risk management, human-factors testing and postmarket monitoring, and urges early testing, cross-functional teams and presubmission meetings.
Medtech Insight - November 6, 2026

Cardinal Health Raises FY2027 Guidance Despite 28% Profit Drop In Medical Products Segment
Cardinal Health raised its fiscal 2027 non-GAAP EPS guidance to $12.80–$13 after first-quarter non-GAAP EPS rose to $3.26, even as medical products segment profit fell 28%. It also signed a binding letter of intent to renew its CVS pharmacy agreements through 2032.
Medtech Insight - November 6, 2026

Reimbursement Before Approval: Blue Arbor’s Strategy To Avoid A Common Device Trap
Blue Arbor Technologies has closed a $10.5m Series A round led by Ottobock. The four-person company is using an FDA pilot to shape its trials around data for future billing codes and will sell only the fully implantable version of its RESTORE nerve interface.
Medtech Insight - November 6, 2026

Solventum Counts On Penetration, Not Market Growth, To Power Growth After HIS Exit
Solventum raised 2026 EPS guidance and says the 3M separation is more than 90% complete after its biggest ERP cutover. Exiting HIS would dilute operating margin by about 400 basis points, and management is counting on penetration, not market growth, to power the remaining company.
Medtech Insight - November 6, 2026

Siemens Healthineers Announces Name Change As Spin-off Looms
Diagnostics carve-out also gets a new name and predicted completion date of mid-2028 as company announces fiscal year 2026 results.
Medtech Insight - November 6, 2026

Over The Counter: Earning The Pharmacist’s Recommendation, With Thorrun Govind
Pharmacist, healthcare lawyer and broadcaster Thorrun Govind tells HBW Insight what consumer health companies can do to earn pharmacists’ trust and recommendations at the counter, as pharmacy teams face growing time and financial pressure.
HBW Insight - November 9, 2026

Estée Lauder Reveals Skin Longevity Platform, L’Occitane Sells Elemis; Beauty Biz Roundup
Estée Lauder unveils Mastering Skin Longevity innovation platform at the China International Import Expo, as PAI Partners announces plan to buy British skin care brand ELEMIS from L’OCCITANE. Coty and e.l.f. Beauty report quarterly sales; Beauty Biz Roundup.
HBW Insight - November 9, 2026

Hikma Chief Cites Success In Stabilizing Generics And Injectables
Referring to 2026 as an “investment, transition and stabilization year,” Hikma CEO Said Darwazah suggested that stability had returned to the company as it offered a third-quarter trading update that forecasted flat 2026 sales for generics and injectables.
Generics Bulletin - November 9, 2026

Sandoz Makes First Semaglutide Launch With Adalvo In Brazil
Sandoz has opened up a major new frontier for its generics business with the launch of its first semaglutide product, in Brazil – where the Adalvo-partnered Owozy version will be marketed by Biolab & Co.
Generics Bulletin - November 9, 2026

Deals Shaping The Industry, Sep 2026
An interactive look at pharma and medtech deals made during September 2026. Data courtesy of Biomedtracker.
In Vivo - November 9, 2026